Premium
BRENTUXIMAB‐VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST‐LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY ( HALO TRIAL).
Author(s) -
Gallamini A.,
Bijou F.,
Viotti J.,
Rossi A.,
Perrot A.,
Patti C.,
Gastaud L.,
Sorasio R.,
Debaigt C.,
Chamorey E.,
Viviani S.,
Thyss A.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_28
Subject(s) - brentuximab vedotin , medicine , bendamustine , abvd , surrogate endpoint , hodgkin's lymphoma , oncology , phases of clinical research , neutropenia , clinical endpoint , lymphoma , gastroenterology , surgery , clinical trial , chemotherapy , hodgkin lymphoma , cyclophosphamide , vincristine , rituximab
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom